A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
brief summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 as a monotherapy or in combination with pembrolizumab in adult patients with selected squamous solid tumors.
detailed description
This Study has a Phase I ALE.P02 monotherapy dose escalation and recommended dose for expansion (RDE) study of ALE.P02 as a monotherapy and combination therapy with pembrolizumab, and a Phase II study of ALE.P02 as a monotherapy at RP2D in adult patients with selected advanced or metastatic Claudin-1 positive (CLDN1+) cancers.
official title
A Phase I/II, Open-Label, Multicenter Study of ALE.P02 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy or in Combination With Pembrolizumab (Anti-PD-1 Antibody) in Adult Patients With Selected Advanced or Metastatic CLDN1+Squamous Solid Tumors